3 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) Eculizumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 143 | 2014-04-11 | 2019-06-26 |
Demyelinating Diseases (2) · Myelitis, Transverse (2) · Neuromyelitis Optica (2) · Optic Neuritis (2) · Recurrence (2) · Hemoglobinuria, Paroxysmal (1)
Alexion Pharmaceuticals, Inc. (2) · Regeneron Pharmaceuticals (1)
United States (3) · Germany (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Argentina (1) · Australia (1) · Canada (1) · Croatia (1) · Czechia (1) · Denmark (1) · Hong Kong (1) · Malaysia (1) · Russia (1)
PMID 31050279, PMID 33310418, PMID 33676197, PMID 34498507, PMID 34803867
2019 (1)